display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
pembrolizumab alone KEYNOTE-564

Study type: